Protomer Technologies

Protomer Technologies is a biotech innovator developing 'smart' therapeutics that can sense and respond to molecular signals in the body, such as glucose. Its core asset is the MEPS platform, a chemical biology-based protein engineering technology used to create conditionally active drugs. Acquired by Eli Lilly in 2021, Protomer operates as an agile subsidiary, with its lead program, a glucose-responsive insulin, now integrated into Lilly's pipeline. The company aims to widen the therapeutic window by creating medicines that are potent only when and where needed.

Molecular Evolution of Peptide Sensors (MEPS) - a chemical biology-based platform that engineers conditionally active therapeutic peptides/proteins whose activity is controlled by sensing specific small molecule activators in the body.

Protomer competes in the emerging field of glucose-responsive insulins with entities like Ziylo (acquired by Novo Nordisk), Sensulin Labs, and various academic institutions. More broadly, its platform competes with other conditional therapeutic technologies (e.g., protease-activated antibodies, pH-sensitive switches) being developed by large pharma and biotech companies for targeted drug activation.